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Introduction {#sec1}
============

The somatosensory system mediates the perception of touch (mechanosensation), pain (nociception), heat (thermosensation), and the position of the body in space (proprioception). These modalities enable us to perceive and react to the environment; they are thus essential for both well-being and survival. Somatosensory information is received peripherally, and then decoded centrally by interneurons (INs) in the dorsal spinal cord ([@bib6]), which relay sensory information to higher-order centers in the brain, including motor systems in the brainstem and cerebellum ([@bib4]), as well as to motor output from the spinal cord. Distinct classes of sensory INs arise during embryonic development: they are classified as dorsal interneuron (dI)1 to dI6s. These neurons have different functional modalities, and arise via distinct developmental programs in different positions in the spinal cord ([@bib26]). For example, the dI1s mediate proprioception ([@bib60]). They are born from the dorsally located ATOH1^+^ (Math1) neural progenitors ([@bib22]), and migrate to deeper position in laminae V-VII of the adult spinal cord upon maturation ([@bib26]). Similarly, the dI2s and dI3s are derived from the NGN1^+^ and ASC1^+^ (Mash1) progenitors, respectively ([@bib21]), and settle in distinct layers of the mature spinal cord. The dI3s mediate touch-activated motor behaviors ([@bib5]), while the functions of the dI2s are currently unknown.

Spinal cord injuries (SCIs) can affect both sensory and motor systems and are debilitating emotionally and physically. SCIs are estimated to affect over 1 million people in the US, reducing their quality of life and costing ∼\$40 billion annually in health care ([@bib3]). SCIs were considered intractable until pluripotent stem cells emerged as a remarkable reagent for understanding disease mechanisms, serving as a platform for drug screening, and providing a source of tissue for cellular replacement therapies. Important milestones toward treating SCIs have been the establishment of protocols to derive spinal motor neurons (MNs) from mouse (m) and human (h) embryonic stem cells (ESCs) ([@bib30], [@bib55]) and induced pluripotent stem cells (iPSCs) ([@bib12], [@bib24]). Stem cell-derived MNs have provided an important window into understanding of the pathology of motor diseases, such as amyotrophic lateral sclerosis ([@bib43]) and spinal muscular atrophy ([@bib13]), as well permitting cellular replacement in injury models ([@bib19], [@bib48]). While these advances raise the possibility of repairing motor functions in SCI patients, relatively little attention has been given to the recovery of sensory circuits that enable the patient to interpret their sensory environment and modulate motor output. In particular, no directed differentiation protocol currently exists to generate sensory spinal INs from human pluripotent stem cells, the critical first step toward recovering somatosensation in SCI patients.

Toward this goal, we have developed a directed differentiation protocol that generates three key populations of dorsal sensory INs: the dI1s, dI2s, and dI3s. This protocol co-opts the developmental mechanisms that first establish these neurons in the embryonic dorsal spinal cord. The spinal cord is derived from the posterior neuroectoderm as a result of both posteriorizing signals, such as retinoic acid (RA) ([@bib11], [@bib36]), and regional identity cues, provided by the HOX genes ([@bib16]). The dorsal-most spinal cord is patterned most notably by the bone morphogenetic protein (BMP) family, secreted by the roof plate (RP) at the dorsal midline ([@bib1], [@bib20], [@bib28], [@bib31], [@bib59]). RP-derived BMPs direct dorsal spinal progenitors toward three populations of dorsal sensory INs; the LHX2^+^ dI1s ([@bib31]), LHX1/5^+^ PAX2^-^ dI2s ([@bib8]), and Isl1/2^+^ TXL3^+^ dI3s ([@bib50]). These neuronal populations fail to develop in mice lacking key type I BMP receptors ([@bib57]) or if the RP is ablated *in vivo* ([@bib29]).

This developmental paradigm suggested that the combinatorial action of RA and BMP4 will caudalize and dorsalize hESC-derived neural progenitors toward dorsal sensory INs, in a manner analogous to the protocols for generating stem cell-derived spinal MNs. However, dorsal sensory INs develop over a different timeline than MNs ([@bib1], [@bib27]) and it has remained unresolved whether hESC-derived spinal progenitors are equally competent to give rise to MNs and INs. We thus first characterized cell fate transitions during the early stages of hESC neuralization to determine the optimal time point to add BMP4. We thereby demonstrated that BMP4 directs hESCs toward dI1 and dI3 fates within a temporally restricted window that is different than that for spinal MNs. Unexpectedly, dI2s are observed in the RA control conditions and are suppressed after BMP4 addition. We further show that hESC-derived sensory INs express mature axonal markers of the spinal cord, suggesting they functionally mirror their endogenous counterparts. Finally, we established that this protocol directs human iPSCs to differentiate into dI1 and dI3s with comparable efficiency with hESCs. Thus, these two types of pluripotent stem cells can follow a similar developmental program to generate sensory INs. Taken together, this study paves the way for further understanding of the diseases of somatosensory system and designing cellular replacement therapies to regain somatosensation in SCI patients.

Results {#sec2}
=======

Characterizing the Timeline by which hESCs Lose Pluripotency and Enter the Neurogenic Lineage {#sec2.1}
---------------------------------------------------------------------------------------------

We sought to generate *in-vitro*-derived dorsal spinal sensory INs by modifying the protocol used to generate spinal MNs ([@bib56]). In brief, this protocol directs hESCs toward MN fates in three steps: hESCs are first cultured in a neural differentiation medium (SaND medium) ([@bib44]), to direct them toward a neurogenic lineage. Second, hESCs are caudalized by the addition of RA ([Figure 1](#fig1){ref-type="fig"}A). Third, they are ventralized by the addition of a sonic hedgehog signaling agonist, such as purmorphamine, to specify spinal MN identity. We hypothesized that adding BMP4 protein, instead of purmorphamine, to the caudalized hESCs would generate BMP-dependent dorsal sensory INs, given the role of the BMPs directing dorsal spinal fate ([@bib1], [@bib31]). However, dorsal sensory INs develop along a different timeline from ventral MNs *in vivo* ([@bib1], [@bib27]). Thus, we first assessed the timing by which hESCs enter the neurogenic and spinal progenitor program, to determine the optimal day on which to add growth factors.Figure 1Timeline for the Onset of the Neurogenic Program in hESCs(A) Timeline and methodological details of the differentiation protocol to derive dorsal spinal sensory INs from hESCs.(B--G) hESCs were collected for IHC and RT-qPCR analyses at day 0, 2 (B and E), 4 (C and F), and 6 (D and G) using antibodies against NANOG (red), PAX6 (green, B--D) SOX1 (green, E--G), SOX2 (blue, B--D), and DAPI (blue, E--G).(H) hESCs rapidly exit the pluripotent state. The number of NANOG^+^ cells (p \< 0.0001) and levels of *NANOG* transcript (O, p \< 0.0001) decline by day 2 (B′) and are undetectable by day 4 (C′ and D′).(I and J) Concomitantly hESCs enter a neurogenic state: *SOX2* transcript and SOX2 protein levels remain constant (I), while *SOX1* mRNA (J, p \< 0.005) and SOX1 protein (J, p \< 0.0001) are induced by day 2. *SOX1* expression starts to decline at day 4 (J), with the number of SOX1^+^ cells decreasing at day 6. By day 6, the remaining SOX1^+^ cells are found clustered together (G). *PAX6* starts to be expressed at day 4 (p \< 0.01) (C‴--D‴ and K).Two biological replicates were performed, with at least five fields of cells quantified for every IHC condition. The number of cells is expressed as a percentage of the total number of DAPI^+^ cells. Probability of similarity ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.0005. Scale bar, 100 μm.

We assessed when hESCs lose pluripotency and enter the neurogenic program by examining the expression levels and distribution of NANOG, SOX2, PAX6, and SOX1 during the first 6 days of two-dimensional culture in SaND medium. NANOG is present specifically in undifferentiated precursors ([@bib35]), SOX2 labels both pluripotent and neuroectodermal cells ([@bib7], [@bib14], [@bib18]), while PAX6 and SOX1 are pan neuroectodermal markers ([@bib40], [@bib53]). The number of NANOG^+^ cells ([Figures 1](#fig1){ref-type="fig"}B′--1D′ and 1H) and *NANOG* mRNA levels ([Figure 1](#fig1){ref-type="fig"}H) decline rapidly by day 2 of the protocol and are undetectable by day 4, suggesting hESCs rapidly exit the pluripotent state ([Figure 1](#fig1){ref-type="fig"}A). In contrast, the number of SOX2^+^ cells ([Figures 1](#fig1){ref-type="fig"}B″--1D″ and 1I) and level of *SOX2* transcript ([Figure 1](#fig1){ref-type="fig"}I) remained stable during this 6-day period, indicating that hESCs start to upregulate the neurogenic program by day 2. This hypothesis was supported by the observation that *PAX6* RNA and PAX6 protein are induced by day 4 and increase by day 6 ([Figures 1](#fig1){ref-type="fig"}B‴--1D‴ and 1J). Similarly, *SOX1* expression initiated in hESCs by day 2 ([Figures 1](#fig1){ref-type="fig"}E--1G and 1K). However, *SOX1* expression subsequently declines, with the numbers of SOX1^+^ cells peaking at day 4, and an ∼5-fold decrease in *SOX1* mRNA by day 6 ([Figure 1](#fig1){ref-type="fig"}K). Together, this analysis suggests that culturing hESCs in SaND medium permits them to initiate neurogenesis. However, this state is not sustained past day 6, suggesting that RA, a pro-neuralization factor ([@bib15], [@bib49]), should be added to the cultures at this time point.

RA Directs hESCs toward Spinal Progenitors with Mixed Identities {#sec2.2}
----------------------------------------------------------------

We next assessed the effect of adding RA at day 6 on neuroepithelial fates in the hESC cultures. hESCs were permitted to form embryoid bodies (EBs) in SaND medium supplemented with 1 μM RA. The levels of both *SOX1* and *PAX6* mRNAs markedly increase, reaching a plateau by day 10 (i.e., after 4 days of RA exposure) ([Figures 2](#fig2){ref-type="fig"}B--2D). *SOX2* mRNA and SOX2 protein levels also modestly increase until day 12 but decline thereafter, suggesting an erosion of the progenitor state ([Figure 2](#fig2){ref-type="fig"}E). The decline in SOX2 levels correlates with the onset of neuronal differentiation. Tuj1, an antibody that labels neural processes ([@bib33]), starts to decorate human EBs (hEBs) at day 10 and becomes robust by day 14 ([Figure 2](#fig2){ref-type="fig"}I), suggesting that progenitors have begun to differentiate into post-mitotic neurons.Figure 2Retinoic Acid Induces Dorsal Spinal Fate in the hESCs(A) At day 6, the neuralized hESCs were dissociated and allowed to form EBs in SaND medium, supplemented with 1 μM RA. Samples were taken at day 6, 8, 10, 12, 14, and 16 for IHC and RT-qPCR analysis to characterize the early effects of RA on EB identity.(B--E) RA promotes neural identity: *SOX1* (B and C) and *PAX6* (B and D) expression increases markedly by day 12. *SOX2* starts to decline by day 12, suggesting the onset of neuronal differentiation (E).(F--H) RA rapidly caudalizes EBs, resulting in a HOXA5^+^ spinal identity from day 10 (G). EBs also show mixed identities, RA promotes both PAX3^+^ dorsal fates by day 8 (F) and OLIG2^+^ ventral fates by day 14 (H).(I) Longer RA incubation induces neural differentiation, marked by Tuj1 expression in EBs (compare quantification on day 10 and day 12, p \< 0.009).Two biological replicates were performed. Scale bar, 100 μm.

We also determined the time frame over which RA induces hEBs toward spinal progenitor fates by analyzing *HOX*, *PAX3*, and *OLIG2* expression. The HOX profile indicates axial level ([@bib41]), PAX3 is broadly present in dorsal spinal progenitors ([@bib32]), and OLIG2 marks the MN progenitor (pMN) domain ([@bib39]). A 2-day exposure to RA (day 8) was sufficient to induce *HOXA5*, with robust numbers of HOXA5^+^ cells observed by day 10 ([Figure 2](#fig2){ref-type="fig"}G). There were markedly more modest levels of *HOXA9* and *HOXA11*, with no expression of either *HOXD11* or *HOXA13* ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E), demonstrating that the hEBs have generally adopted a rostral cervical spinal identity. However, the EBs contain both dorsal and ventral spinal progenitors: *PAX3* mRNA and PAX3 protein are present at high levels by day 8 ([Figure 2](#fig2){ref-type="fig"}F), while *OLIG2* expression starts at day 10, but is not robust until day 16, when many OLIG2^+^ cells are also observed ([Figure 2](#fig2){ref-type="fig"}H). Thus, there are two phases of RA action: an early phase (day 6--10) where RA induces dorsal spinal progenitors, and a later phase (after day 12), when prolonged exposure to RA results in ventral spinal progenitors and the onset of neuronal differentiation.

BMP4 Induces hEBs toward Dorsal Sensory IN Fates within a Specific Temporal Window {#sec2.3}
----------------------------------------------------------------------------------

We next determined the consequence of adding BMP4 in addition to RA to the hEB cultures. Previous studies ([@bib1], [@bib9], [@bib28]) have shown that BMP4 is sufficient to direct ectopic Lhx2^+^ dI1, Lhx1/5^+^ Pax2^-^ dI2 and Isl1^+^ Tlx3^+^ dI3 cells in embryonic chicken spinal cords. We verified that these markers of dorsal IN identity are evolutionarily conserved in primates, by assessing the distribution of Lhx2 and Isl1 in day 28 Rhesus macaque embryos, a stage equivalent to embryonic (E) stage 11.5 mouse ([@bib10]). Strikingly, the distribution of Lhx2 and Isl1 were similar in primates and rodents ([Figures 3](#fig3){ref-type="fig"}B, 3C, [4](#fig4){ref-type="fig"}A, and 4B).Figure 3BMP4 Directs hESCs toward Proprioceptive-dI1 Sensory Interneurons(A) BMP4 was added to neuralized EBs at day 6 (BMP4-D6), 8 (BMP4-D8), 10 (BMP4-D10), or 17 (BMP4-D17). EBs were collected at day 36 for IHC and RT-qPCR analyses to characterize the effects of BMP4 on dorsal neural identity.(B and C) Transverse sections of E11.5 mouse lumbar (B) and day 28 monkey thoracic (C) embryonic spinal cord labeled with antibodies against β-III tubulin (red, Tuj1) and Lhx2 (green). The Lhx2^+^ Tuj1^+^proprioceptive dI1s originate in the dorsal-most spinal cord (B, box, B′).(D--I) The addition of BMP4 at day 6 (E), 8 or 10 (F) resulted in elevated *LHX2* expression (H) and significantly increased production of LHX2^+^ Tuj^+^ dI1s (E″, F″, and I) compared with RA controls (D″ and I; probability similar to RA control: p = 0.25, BMP4-D6; p \< 0.043, BMP4-D8; p \< 0.016, BMP4-D10); ∼20% of the BMP4-treated cells are LHX2^+^ (I). However, this effect is lost if BMP4 is added at day 17 (G, H, and I; probability similar to RA control, p = 0.20). There is no significance difference in *LHX2* expression levels or numbers of LHX2^+^ Tuj^+^ dI1s among the BMP4-D6, BMP4-D8, and BMP4-D10 conditions (L, p = 0.77, BMP4-D6 versus BMP4-D8 versus BMP4-D10, one-way ANOVA). Note that in the RA condition, not all LHX2^+^ cells are Tuj1^+^ (arrows, D″). The region in the white dashed box in (D)--(G) is shown at higher magnification in (D′)--(G′) and (D″)--(G″).Probability of similarity ^∗^p \< 0.05, ^∗∗∗^p \< 0.0005. Six biological replicates were performed, with 20--25 EBs quantified. The number of cells was normalized to the area of the EB and then scaled according to a unit area (10,000 μm^2^). Scale bar, 100 μm.Figure 4BMP4 Directs hESCs toward Mechanosensory-dI3 Interneurons(A and B) Transverse sections of E11.5 mouse lumbar (A) and day 28 Rhesus macaque thoracic (B) embryonic spinal cord labeled with antibodies against β-III tubulin (red, Tuj1) and Isl1 (green). The Isl1^+^ Tuj1^+^ mechanosensory dI3 cells are present in the intermediate spinal cord (A, box, A′).(C--H) Addition of BMP4 at day 6 (D), 8 or 10 (E) resulted in elevated *ISL1* expression (G) and significantly increased production of ISL1^+^ Tuj^+^ dI3s (arrowheads, D″, E″, quantified in H) compared with RA controls (C″ and H; probability similar to RA control: p \< 0.004, BMP4-D6; p \< 0.0001, BMP4-D8; p \< 0.0008, BMP4-D10); ∼15% of the BMP4-treated cells are ISL1^+^ (H). However, this effect is lost when BMP4 is added at day 17 (F″, G, and H, probability similar to RA control, p \> 0.09). There is no significant difference in *ISL1* levels or numbers of ISL1^+^ Tuj^+^ dI3s in the BMP4-D6, BMP4-D8 and BMP4-D10 conditions (L, BMP4-D6 versus BMP4-D8 versus BMP4-D10, p \> 0.37, one-way ANOVA). Note that not all ISL1^+^ cells are Tuj1^+^ (dotted lines, D″, and E″). The region in the white dashed box in (C)--(F) is shown in higher magnification in (C′)--(F′) and (C″)--(F″).Probability of similarity ^∗^p \< 0.05, ^∗∗∗^p \< 0.0005. Six biological replicates were performed with 14--27 EBs quantified. The number of cells was normalized and then scaled according to a unit area (10,000 μm^2^). Scale bar, 100 μm.

We hypothesized that the addition of BMP4 to hEBs exposed to a short period of RA (i.e., from day 6 to 10 before either ventralization or neuronal differentiation) would be the condition most likely to induce dorsal sensory INs. BMP4 (10 ng/mL) was added to the RA-treated hEBs at day 6, 8, 10, and 17 ([Figure 3](#fig3){ref-type="fig"}A). The hEBs were cultured until day 36 and then analyzed for the distribution and level of SOX2, pHISTONEH3, LHX2, LHX1/5, ISL1, and PAX2. The EBs are still differentiating at day 36, with 1%--2% of the cells in mitosis ([Figures S2](#mmc1){ref-type="supplementary-material"}A′--S2D′ and S2J), and up to ∼50% of the cells in the EBs continuing to express SOX2 ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2D and S2I).

Consistent with our hypothesis, the addition of BMP4 on any day during the RA-early phase (i.e., BMP4-D6, BMP4-D8, and BMP4-D10) resulted in an up to 3-fold increase in the expression of *LHX2* and a \>2-fold increase in the number of LHX2^+^ Tuj1^+^ dI1s ([Figures 3](#fig3){ref-type="fig"}E, 3F, 3H, and 3I, see [Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C for biological replicates) compared with RA control ([Figures 3](#fig3){ref-type="fig"}D, 3H, and 3I). Measuring the number of LHX2^+^/DAPI^+^ nuclei within EBs suggested an average dI1 differentiation efficiency of ∼20% ([Figure 3](#fig3){ref-type="fig"}I, summarized in [Table S3](#mmc1){ref-type="supplementary-material"}). In contrast, there was no significant increase in either *LHX2* expression or the number of LHX2^+^ Tuj1^+^ cells, when BMP4 was added during the RA-late phase (i.e., BMP4-D17) ([Figures 3](#fig3){ref-type="fig"}G, 3H, and 3I).

Similarly, the addition of BMP4 to hEBs during the RA-early phase led to 3-fold increased *ISL1* expression and up to 3-fold more ISL1^+^ Tuj1^+^ cells ([Figures 4](#fig4){ref-type="fig"}D, 4E, 4G, and 4H, see [Figures S3](#mmc1){ref-type="supplementary-material"}D--S3F for biological replicates) compared with RA control ([Figures 4](#fig4){ref-type="fig"}C, 4G, and 4H). These ISL1^+^ cells could be co-labeled with TLX3, which marks a subset of dI3s ([@bib37]) ([Figures S4](#mmc1){ref-type="supplementary-material"}B, S4C, and S4E--S4G), but not with HB9, a marker of spinal MNs ([@bib2]) ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4H), verifying their identity as dorsal dI3s. The average dI3 differentiation efficiency is ∼15% ([Figure 4](#fig4){ref-type="fig"}H, [Table S3](#mmc1){ref-type="supplementary-material"}). There was again no significant increase in either *ISL1* expression or the number of ISL1^+^ Tuj1^+^ cells, when BMP4 was added during the RA-late phase ([Figures 4](#fig4){ref-type="fig"}F, 4G, and 4H).

Surprisingly, we did not find a condition where the addition of RA + BMP4 was able to induce dI2s, as was observed in chicken embryos *in vivo* ([@bib1]). Rather we found that LHX1/5^+^ PAX2^−^ dI2s are present in the RA condition ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2K--S2N), with an average dI2 differentiation efficiency of ∼15% ([Figure S2](#mmc1){ref-type="supplementary-material"}K and [Table S3](#mmc1){ref-type="supplementary-material"}). In contrast, BMP4 appears to suppress the dI2 fate: after the addition of RA + BMP4 there is a 10-fold decrease in *LHX1* or *LHX5* expression and at least a 5-fold decrease in the number of LHX1/5^+^ PAX2^−^ cells ([Figures S2](#mmc1){ref-type="supplementary-material"}F, S2G, and S2K--S2N).

Taken together, these data suggest that neural progenitors are most competent to generate BMP4-derived dorsal sensory INs after a brief exposure to RA. Supporting this model, we find that *ATOH1* and *ASCL1* expression is increased in hEBs after early BMP4 addition ([Figures 5](#fig5){ref-type="fig"}D and 5E). *ATOH1* (also known as Math1) and *ASCL1* (also known as Mash1) expression defines the progenitor state for the dI1s (i.e., the dorsal progenitor \[dP\] 1 domain) ([Figure 5](#fig5){ref-type="fig"}B ([@bib22])) and dI3s (i.e., dP3) ([Figure 5](#fig5){ref-type="fig"}C, [@bib21]), respectively. This competence window has closed by 11 days (day 17) of RA treatment.Figure 5BMP4 Directs hESCs toward Dorsal Neural Progenitor Identities(A) To assess the acquisition of dorsal progenitor identity, EBs were cultured for 12 days, with BMP4 added at day 6.(B and C) In the mouse spinal cord (indicated by yellow dotted lines, B and C), the dP1 and dP3-5 domains express *Atoh1* (arrowheads, B) and *Ascl1* (arrowheads, C), respectively, in the E11.5 mouse embryo. The dP1 cells give rise to Lhx2^+^ dI1s while Isl1^+^ dI3s emerge from the dP3-5 population.(D and E) BMP4 addition increases *ATOH1* levels by \>2-fold (D, probability of similarity with RA control, p \< 0.038) and *ASCL1* levels by \>5-fold (E, p \< 0.024).Four biological replicates were performed. Scale bar, 100 μm.

Differentiated hEBs Exhibit Mature Axonal Markers of the Dorsal Spinal Cord {#sec2.4}
---------------------------------------------------------------------------

We next started to assess whether our directed differentiation protocol generates dorsal INs with the relevant functional characteristics, by analyzing day 36 hEBs for the presence of ROBO3 and DCC. DCC ([@bib25]) and ROBO3 ([@bib42]) are transmembrane receptors required for the guidance of spinal commissural axons. The presence of ROBO3 and DCC in the spinal cord is evolutionarily conserved between rodents and primates; however, there may be species-specific differences. While both Dcc and Robo3 are present broadly in axons crossing the ventral commissure in E11.5 mouse embryos ([Figures 6](#fig6){ref-type="fig"}A and 6C), Dcc and Robo3 have sparser distribution in day 28 monkey spinal cords. Dcc is generally present on axons in the dorsal spinal cord (arrows, [Figure 6](#fig6){ref-type="fig"}B′), while Robo3 is present on the soma of neurons in the intermediate spinal cord (arrows, [Figure 6](#fig6){ref-type="fig"}D′) as well as pioneering commissural axons in the ventral spinal cord.Figure 6hESC-Derived EBs Express DCC and ROBO3, Two Markers of Spinal Commissural Axons(A--D) Transverse sections of E11.5 mouse lumbar (A and C) and day 28 monkey thoracic (B and D) spinal cord labeled with antibodies against Tuj1 (red), Dcc (green, A and B), Robo3 (green, C and D) and DAPI (blue). Dcc and Robo3 are broadly present on mouse commissural (A′ and C′) axons. In contrast, Robo3 is present in a sparser population of monkey commissural axons arising from neurons in the intermediate spinal cord (arrowheads, D′). Dcc decorates the axons of dorsally derived commissural neurons (arrowheads, B′).(E--H) Day 36 EBs treated with RA, RA + BMP4-D6, RA + BMP4-D10 and RA + BMP4-D17, were labeled with antibodies against Tuj1 (red), DCC (green, E--H) and ROBO3 (green, I--L). Numerous DCC^+^ Tuj1^+^ and ROBO3^+^ Tuj1^+^ axons were present in the control and experimental EBs. The ROBO3 and DCC stainings are more extensive in the RA control (E′ and I′) and BMP4-D17 EBs (H′ and L′), compared with BMP4-D6 (F′ and J′) and BMP4-D10 (G′ and K′) EBs, consistent with these conditions generating cells with distinct dorsal identities.Scale bar, 100 μm.

Both DCC and ROBO3 are present in RA control and RA + BMP4-treated EBs by day 36. However, the DCC^+^ ROBO3^low^ expression profile in the BMP4-D6 and BMP4-D10 hEBs ([Figures 6](#fig6){ref-type="fig"}F′, 6G′, 6J′, and 6K′) was distinct from the DCC^+^ ROBO3^high^ profile ([Figures 6](#fig6){ref-type="fig"}E′, 6H′, 6I′, and 6L′) observed in the RA control and BMP4-D17 condition. These profiles are consistent with the BMP4-D6 and BMP4-D10 conditions primarily inducing the dorsal-most dI1 spinal identity, while the RA and BMP4-D17 condition results in more intermediate dorsal identities. Thus, these hESC-derived dorsal INs have the expected complement of guidance receptors, consistent with the hypothesis that they are maturing into functional dorsal sensory neurons.

BMP4 Can Direct Human iPSCs toward dI1s and dI3s Fates {#sec2.5}
------------------------------------------------------

Finally, we assessed whether our protocol can be used to direct patient-derived iPSCs toward the dI1 and dI3 fates. BMP4 was added to iPSCs at day 10, and EBs collected at day 36. As observed for hESCs, we found a 4-fold increase in *LHX2* expression ([Figure 7](#fig7){ref-type="fig"}C) and a 2-fold increase in the number of LHX2^+^ Tuj1^+^ dI1s ([Figures 7](#fig7){ref-type="fig"}B′ and 7D) in the BMP4-D10 treated hEBs compared with RA control ([Figure 7](#fig7){ref-type="fig"}A′). We also observed a 2.5-fold increase in *ISL1* expression ([Figure 7](#fig7){ref-type="fig"}G) and a 2-fold increase in the number of ISL1^+^ Tuj1^+^ dI3s ([Figures 7](#fig7){ref-type="fig"}F′ and 7H) in the BMP4-D10-treated hEBs compared with RA control ([Figure 7](#fig7){ref-type="fig"}E′). Side-by-side differentiation procedures suggested that hESCs and iPSCs generated dI1 and dI3 sensory INs to comparable extents ([Figures 7](#fig7){ref-type="fig"}C, 7D, 7G, and 7H). Thus, this protocol is capable of deriving patient-specific sensory IN populations.Figure 7BMP4 Also Directs iPSCs toward a dI1s and dI3 Identity(A--H) Day 36 EBs, derived from iPSCs treated with RA and RA + BMP4-D10, were either processed for RT-qPCR or labeled with antibodies against Tuj1 (red), LHX2 (green, A and B), ISL1 (green, E and F), and DAPI (blue).(A--D) The BMP4-D10 condition resulted in a significant increase in *LHX2* mRNA and number of LHX2^+^ Tuj1^+^ dI1s in both hESC-derived EBs (C, probability similarity with RA control p \< 0.023; D, p \< 0.0001) and iPSC-derived EBs (C, p \< 0.0096; B′ and D, p \< 0.0001) compared with RA control (arrow, A′ and D).(E--H) The BMP4-D10 condition also resulted in a significant increase in *ISL1* expression in hESCs-EBs (G, p \< 0.016) and iPSC-EBs (G, p \< 0.04) and the number of ISL1^+^ Tuj1^+^ dI3s (hESCs-EBs: H, p \< 0.0005; iPSC-EBs: F′ and H, p \< 0.0022), compared with RA control (E′, G, and H).Three biological replicates were performed. Probability of similarity: ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.0005. Three biological replicates were performed with 10--18 EBs quantified. The number of cells was normalized and then scaled according to a unit area (10,000 μm^2^). Scale bar, 100 μm.

Discussion {#sec3}
==========

Human PSC technologies can generate the unlimited supply of cells needed to facilitate both cellular replacement therapies, and an understanding of the molecular details underlying human diseases. To date, significant progress has been made deriving spinal MNs from hESCs and iPSCs that would permit the recovery of coordinated movement ([@bib19], [@bib34], [@bib55]). However, to regain full function, a second critical class of neurons is needed: the dorsal sensory INs that integrate and relay somatosensory information from the periphery to the brain. Here, we report on the development of a robust protocol that permits the derivation of spinal sensory INs from hESCs and hiPSCs by the sequential addition of RA ± BMP4.

Establishing the Timeline over which hESCs Are Neuralized and Become Differentially Competent {#sec3.1}
---------------------------------------------------------------------------------------------

We used the well-defined spinal MN-directed differentiation protocol as our starting point in our studies, hypothesizing that these hESC-derived neural progenitors are competent to become multiple post-mitotic neuronal identities. We first characterized hESCs as they acquire neural and spinal identity. The onset of hESC neuroectodermal identity is marked by a rapid decline in pluripotency and the upregulation of SOX1 and then PAX6 ([Figure 1](#fig1){ref-type="fig"}). This temporal order is similar to that observed during mouse neuroectodermal development ([@bib40], [@bib47]), suggesting that we have recapitulated a development program conserved between rodents and humans. Previous hESC neuralization protocols have reported an inverted temporal order of *SOX1* and *PAX6* expression as hESCs neuralize ([@bib17], [@bib58]). This discrepancy may arise from the way in which neuroectodermal identity was achieved: the previous studies used noggin to facilitate neuralization by blocking BMP signaling, and basic fibroblast growth factor (bFGF) to maintain the proliferation capacity of the neural progenitors. However, we neuralized hESCs using the B27/N2 supplements present in SaND medium, which may result in hESCs initiating neurogenesis in a manner closer to the endogenous process.

We found that RA should be added at day 6 to maintain a stable SOX1^+^ PAX6^+^ neurectodermal identity. By day 12, these cells had a HOX profile most consistent with a HOXA5^+^ cervical spinal identity ([Figure 2](#fig2){ref-type="fig"}G), with a small component from the HOXA9^+^ thoracic level ([Figure S1](#mmc1){ref-type="supplementary-material"}). There is little to no *HOXD11* or *HOXA13* expression ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E), suggesting that the cells do not have a lower lumbar-sacral identity. The HOX profile may depend on the concentration and duration of RA exposure, as well as the presence of other caudalizing factors. Studies using a combination of RA and FGF2 have generated spinal neurons with a more posterior HOX gene profile ([@bib30]).

The Competence State of hESC-Derived Spinal Progenitors Changes over Time {#sec3.2}
-------------------------------------------------------------------------

We assessed whether hESC-derived spinal progenitors are simultaneously competent to give rise to either MNs or INs, or whether the competence state changes over time. We found that that the addition of RA induces PAX3^+^ dorsal progenitors by day 8, while OLIG2^+^ ventral progenitors arise later, by day 14. Consistent with the hypothesis that progenitor competence state changes over time, early RA-treated spinal progenitors are most competent to give rise to dI1 and dI3s in response to BMP4. This competence for dorsalization is lost by day 17, the day at which purmorphamine is typically added to hESC-derived spinal progenitors to direct them toward MN fates ([@bib44]). The molecular basis for these different competence states remains unresolved. Longer RA incubation may alter the transcriptome of the hESCs-derived spinal progenitors, rendering them unresponsive to BMP4.

Unexpectedly, we were unable to derive BMP4-dependent dI2s; these cells were only observed in the RA condition. In the developing spinal cord, BMP signaling is both necessary and sufficient to specify the dI2 fate ([@bib1], [@bib57]). However, our recent experiments have suggested that dorsal progenitors are not equivalently competent to respond to BMP4 ([@bib1]). We have found that BMP4 is both a patterning and differentiation signal for dI1/dI3s, able to specify dP1/dP3 progenitors and then reiteratively direct them to form dI1s and dI3s. In contrast, BMP4 is specifically a differentiation cue for dI2s: it directs Ngn2^+^ progenitors to differentiate into dI2s. Taken together, our studies suggest adding BMP4 to hESCs directs them first toward a dP1/dP3 progenitor state; the continued presence of BMP4 then acts as pro-dI1/dI3 signal. The dP2 progenitor state is suppressed, thereby generating no BMP4-dependent dI2s. In contrast, adding RA to hESCs appears to generate multiple dorsal progenitor populations, which in turn results in mixed dorsal IN identities, including some dI1s, the more robust production of dI2s, as well as more intermediate dorsal INs, such as dI4s ([Table S3](#mmc1){ref-type="supplementary-material"}).

Future studies will identify the mechanism by which BMP4 produces both dI1s and dI3s. Does BMP4 induce a common dP1/dI3 progenitor state? Or do fluctuations in BMP signaling specify distinct dP1 and dP3 populations? We will also investigate how to deploy BMP signaling to improve the efficiency by which spinal progenitors are directed to become dI2s.

hESC-Derived Sensory INs May Functionally Mirror Their Endogenous Counterparts {#sec3.3}
------------------------------------------------------------------------------

The addition of BMP4 to the hESCs cultures led to ∼35% of the cells in an hEB becoming dI1s and dI3s ([Table S3](#mmc1){ref-type="supplementary-material"}). To start to address whether these neurons functionally resemble their endogenous counterparts, we assessed whether the hESC-derived human sensory INs express DCC and ROBO3, the guidance receptors required for growth of commissural axons toward the ventral midline ([@bib42], [@bib52]). DCC is present in hEBs at high levels as predicted from the distribution of Dcc in both mouse and monkey. However, the number of ROBO3^+^ neurons was lower than we anticipated in the BMP4-directed hEBs compared with the RA control. Mouse Robo3 is present at high levels on commissural neurons and their axons throughout the dorsal and intermediate spinal cord ([@bib42], [@bib51], [@bib52]). However, monkey Robo3 is primarily present on intermediate spinal neurons, and that the pioneering commissural axons appear to stem from this intermediate population ([Figure 6](#fig6){ref-type="fig"}D′). Thus, there may be species-specific differences in the complement of axonal guidance receptors present on dorsal neurons, and the timing by which sensory circuitry is established. The functional implications of this finding require further studies; however, one possibility is that DCC^+^ ROBO3^low^ is the correct complement of axonal receptors for primate dI1 neurons. An alternative hypothesis is that the presence of BMP4 inhibits the maturation process of the spinal INs thereby reducing the ROBO3 levels.

In future studies, we will assess how closely the transcriptomic and electrophysiological profiles of hESC-derived sensory INs mirror neurons *in vivo.* Complicating this analysis, these properties have not yet been well defined for the endogenous sensory INs.

Clinical Implications of These Studies {#sec3.4}
--------------------------------------

For this protocol to be clinically relevant, it must also be applicable to patient-derived iPSCs. Previous studies have shown that differences in the epigenetic landscape can result in iPSC lines having varied differentiation efficiencies compared with hESCs ([@bib23]). However, we found no noticeable difference between an iPSC and hESC line with respect to their ability to generate dI1s and dI3s. Thus, our protocol is robust and can be used to derive patient-specific sensory INs.

The present study completes the first step toward functionally re-building damaged spinal cords, by reestablishing the sensory connections that would allow an injured patient to perceive external stimuli. *In-vitro*-derived sensory INs can be used in drug testing platforms targeting diseased sensory INs as well as investigating the feasibility of using them in cellular replacement therapies. The ability to generate spinal INs *in vitro* will also accelerate studies examining the basis of debilitating spinal dysfunctions, such as congenital pain insensitivity and hereditary sensory and autonomic neuropathies ([@bib38]).

Experimental Procedures {#sec4}
=======================

Human ESC and iPSC Culture and Differentiation {#sec4.1}
----------------------------------------------

H9 hESCs and iPSCs were obtained from the University of California, Los Angeles (UCLA) stem cell core and iPSC core at Cedars Sinai Medical Center, Los Angeles, respectively. Cells were maintained on Geltrex (Thermo Fisher Scientific)-coated plates in mTeSR1 medium (Stem Cell Technologies) at 37°C and in 5% CO~2~ humidified incubators. Neural differentiation was initiated in two-dimensional culture by replacing mTeSR1 with SaND medium (IMDM + 2% B27-VitA + 1% N2 supplement; Thermo Fisher Scientific) ([@bib44]) for 6 days. After 6 days, hESCs or iPSCs were treated with Accutase (STEMCELL Technologies) for 2 min at 37°C, scraped off the plate using a glass pipette (Fisher Scientific) and collected by centrifugation at 1000 rpm in SaND medium. The cell pellet was resuspended in SaND medium + 1 μM all-*trans* RA (Sigma-Aldrich) + ROCK inhibitors (BioPioneer; SM-008), and the cells were permitted to form EBs in low-attachment 24-well plates (Corning). To induce dorsal IN differentiation ([Figure 1](#fig1){ref-type="fig"}A), 10 ng/mL BMP4 recombinant protein (Invitrogen, catalog no. PHC9534) was added at different time points between day 6 and day 17 ([Figure 3](#fig3){ref-type="fig"}A). At day 17, EBs were transferred to neural differentiation medium (NBDM) ([@bib44]) supplemented with 1 μM RA+ 10 ng/mL BMP4 for a further 8 days. To facilitate neuronal maturation, EBs were grown in neural maturation medium, consisting of Dulbecco\'s modified Eagle\'s medium∖F12 and supplemented with B27 (2%), RA (1 μM), BMP4 (10 ng/mL), dibutyryl cyclic AMP (1 μM), ascorbic acid (200 ng/mL) until day 36 ([@bib44]). Control EBs were grown in 1 μM RA up until day 36.

Immunohistochemistry {#sec4.2}
--------------------

### Cells {#sec4.2.1}

Adherent hESC cultures were fixed with 4% paraformaldehyde (PFA) (Thermo Fisher Scientific, NC9658705) for 10 min at room temperature, and then washed with 1× PBS. EBs were fixed with 4% PFA for 30 min on ice, washed with 1× PBS, cryopreserved in a 30% sucrose solution, and thin sectioned to yield 12 μm sections. All cells were blocked (1% heat-inactivated horse serum + 0.1% Triton X-100 + 0.01% NaAz) for 1 hr and incubated with primary antibodies (see [Table S1](#mmc1){ref-type="supplementary-material"}) overnight at 4°C. Species-appropriate cyanine 3, cyanine 5, and fluorescein-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories) were used at room temperature for 2 hr.

### Tissue Sections {#sec4.2.2}

Mouse tissue was processed for immunohistochemistry (IHC) as previously described ([@bib52]). Embryonic day 28 Rhesus macaque spinal cord was obtained through timed matings following Animal Care and Use Committee Approval ([@bib10]). Embryos were fixed in 4% PFA, embedded in paraffin blocks, then cut to obtain 5-μm-thick transverse sections. For IHC staining, sections were deparaffinized and then rehydrated through a xylen/ethanol gradient. Sections were processed for immunohistochemistry as previously described ([@bib10]). An antigen retrieval step using Tris-EDTA (10 mM Tris base, 1 mM EDTA solution, 0.05% Tween 20 \[pH 9.0\]) buffer at 95°C for 40 min was necessary. For nuclei staining, cells or sections were incubated with DAPI (1:1,000) in 1× PBS for 5 min and washed two times in 1× PBS. The sections were mounted in ProLong Gold mounting media (Thermo Fisher Scientific).

Imaging and Quantification {#sec4.3}
--------------------------

Images of adherent hESC cultures and EB sections were collected on an LSM800 confocal microscope using Carl Zeiss Zen Blue and processed using Adobe Photoshop CS6 software. The number of cells in adherent cultures were counted using the NIH ImageJ particle module, after modulating the intensity threshold in 8-bit images to capture the fluorescent cells. For the hESC counts ([Figure 1](#fig1){ref-type="fig"}) and differentiation efficiencies ([Table S3](#mmc1){ref-type="supplementary-material"}), the number of cells is expressed as a percentage of the total number of DAPI^+^ cells. For the EB cell counts ([Figures 3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, and [7](#fig7){ref-type="fig"}), the number of cells is divided by the area of the EB and then scaled according to a unit area (10,000 μm^2^). Data points were pooled from multiple experiments.

Statistics {#sec4.4}
----------

We performed each experiment 2--6 independent times (biological replicate), with 2--3 technical replicates (qPCR or IHC) for each biological replicate. Statistical analyses were performed using either a two-tailed Student\'s t test, if the data fit a normal distribution (Anderson-Darling test), or a Mann-Whitney test, if it did not. All data are represented as means ± SEM.

RNA Isolation and RT-qPCR Analysis {#sec4.5}
----------------------------------

RNA was extracted using the RNeasy purification kit (QIAGEN, catalog no. 74104). cDNA was synthesized using Superscript IV (Thermo Fisher Scientific). RT-qPCR was always performed in triplicate using SYBR Green Master Mix (Roche) on a Roche RT-qPCR machine using gene-specific primers ([Table S2](#mmc1){ref-type="supplementary-material"}). Sequences for primer pairs for HoxA11 (primer ID-84105266c2) and HoxA13 (primer ID-171906561c1) were obtained from PrimerBank-MGH-PGA ([@bib45], [@bib46], [@bib54]). The Ct values for each gene were calculated by averaging two runs for each condition. Expression of the target gene was normalized with the expression of glyceraldehyde-3-phosphaste dehydrogenase (GAPDH) and fold change was calculated using the 2^−ΔΔCt^ method. We observed the same trends in all experiments, (i.e., the effect of RA versus RA + BMP4 in different biological replicates was always reproducible). However, the magnitude of the fold change in gene expression could vary markedly between biological replicates ([Figure S3](#mmc1){ref-type="supplementary-material"}). Thus, each RT-PCR graph is taken from one of the biological replicates, and does not include statistics as required by the journal.

Ethical Statement {#sec4.6}
-----------------
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